Yes. Thiazolidinediones, a group of medicines used to treat type 2 diabetes, can make the body hold on to extra fluid. This may cause swelling in the feet, ankles, or legs and lead to weight gain. In some people, the extra fluid can cause heart failure or make existing heart failure worse. The risk is especially important when these medicines are taken with insulin.
Which thiazolidinediones can cause fluid retention?
Thiazolidinediones, also called TZDs, are medicines that help the body respond better to insulin and control blood sugar. Pioglitazone and rosiglitazone are examples of this drug class. Although these medicines can help manage type 2 diabetes, fluid retention is a recognized side effect that healthcare professionals consider when prescribing and monitoring treatment.
Fluid retention means that the body holds on to more fluid than it should. When this happens, fluid may collect in tissues and cause swelling, also known as edema. The extra fluid can also contribute to weight gain. The U.S. National Library of Medicine's DailyMed prescribing information for pioglitazone warns that this effect can be dose-related and may occur when the medicine is taken alone or with other diabetes treatments.
How do thiazolidinediones lead to fluid retention?
These medicines can affect how the body regulates fluid, leading to an increase in the amount of fluid circulating in the body or collecting in tissues. The resulting buildup can become a concern when it places additional demands on the heart. The exact effects depend on the individual, the medication dose, and other health conditions.
Fluid retention and heart failure are closely connected in this context. Heart failure occurs when the heart cannot pump blood well enough to meet the body's needs. Extra fluid can contribute to the development of heart failure in some people or worsen an existing case. This does not mean that everyone taking a thiazolidinedione will develop heart failure, but the known risk makes changes in swelling, weight, or breathing important to report.
Who has a greater risk of fluid retention?
Although fluid retention can occur in different circumstances, certain situations deserve particular attention during treatment with thiazolidinediones:
- Taking insulin at the same time: Fluid retention is more common when pioglitazone is used with insulin than when it is used alone.
- Taking a higher medication dose: The prescribing information describes dose-related fluid retention, meaning the likelihood or extent of this side effect may increase with the dose.
- Having heart failure: Extra fluid may worsen an existing heart condition, making the choice of diabetes medicine especially important.
- Already having swelling: Existing edema may need closer observation because treatment can contribute to new or worsening fluid retention.
The American Diabetes Association's 2026 Standards of Care in Diabetes identifies a consistent relationship between thiazolidinediones and an increased risk of heart failure and recommends avoiding these medicines in people with heart failure. A healthcare professional can consider the person's heart health, diabetes treatment needs, and other medical circumstances when selecting medication.
What signs of fluid retention should you watch for?
Fluid retention may cause visible changes or symptoms that develop gradually. These experiences are not specific to medication-related fluid buildup, but they are important to discuss with a healthcare professional when taking a thiazolidinedione.
- Swelling in the feet, ankles, lower legs, or hands.
- Weight gain over a short period without an obvious explanation.
- Swelling or discomfort in the abdomen.
- Shortness of breath during normal activities or when lying down.
- Waking during the night because of difficulty breathing.
- Unusual tiredness, reduced ability to exercise, or a persistent cough accompanied by breathing changes.
MedlinePlus, a service of the U.S. National Library of Medicine, advises people taking pioglitazone to report symptoms such as rapid weight gain, swelling, or shortness of breath immediately, especially after starting treatment or increasing the dose. These changes can be signs of heart failure and should not be ignored.
Seek emergency medical care for severe or sudden difficulty breathing. New or worsening swelling, unexplained rapid weight gain, or a change in breathing should be reported promptly to the prescribing healthcare professional, even if the symptoms do not seem severe.
How do healthcare professionals assess fluid retention?
When fluid retention is suspected, a healthcare professional considers when the symptoms began, whether the thiazolidinedione dose recently changed, and whether other medicines are being taken. They may review changes in body weight, examine areas of swelling, and assess breathing and heart function. Depending on the findings, additional tests may be needed to investigate heart problems or other possible causes of the symptoms.
Monitoring also helps identify changes before they become more disruptive. The NHS Specialist Pharmacy Service guidance on pioglitazone monitoring includes periodic weight checks because weight gain may reflect fluid retention and can be a sign of heart failure. Following an individualized monitoring plan can help the healthcare team assess whether treatment remains appropriate.
What happens if a thiazolidinedione causes fluid retention?
The next step depends on the amount of fluid buildup, any accompanying symptoms, the person's heart health, and the benefits of the medication for diabetes control. If heart failure develops, the prescribing information states that the need to reduce the dose or discontinue pioglitazone must be considered. These decisions should be made by the treating healthcare professional rather than by changing the treatment independently.
A clinician may review the current dose and other diabetes medicines, assess whether heart failure or another condition is contributing to the symptoms, and decide whether a different treatment is more suitable. If heart failure is present, it may also require specific treatment. The appropriate approach depends on the clinical findings, rather than swelling alone.
Do not take additional diuretics, commonly called water pills, or change the dose of prescribed medicines on your own to manage swelling. Doing so without guidance may interfere with blood pressure, fluid balance, or other aspects of care. Prompt assessment helps determine the safest way to address the problem while maintaining appropriate blood sugar management.
Can fluid retention be prevented while taking these medicines?
Fluid retention cannot always be prevented, but careful prescribing and monitoring can help identify concerns early. Before treatment begins, tell the prescribing professional about any history of heart failure, existing swelling, or medicines you take alongside your diabetes treatment. This information can help determine whether a thiazolidinedione is appropriate and what monitoring is needed.
After starting treatment or changing the dose, follow the monitoring instructions provided by the healthcare team. Report new swelling, unexplained rapid weight gain, or changes in breathing promptly rather than waiting for a routine appointment. If you have heart failure or develop symptoms that may suggest it, your healthcare professional can reassess the risks and benefits of continuing the medicine.
The key point is that thiazolidinediones can cause fluid retention, but the consequences are not the same for everyone. Recognizing the possible connection and discussing new symptoms early can help the healthcare team make informed decisions about diabetes treatment and heart health.